Retrophin (RTRX) versus The Competition Critical Review
Retrophin (NASDAQ: RTRX) is one of 282 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Retrophin to related businesses based on the strength of its dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.
This is a summary of current recommendations and price targets for Retrophin and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Retrophin currently has a consensus price target of $36.00, suggesting a potential upside of 68.07%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.28%. Given Retrophin’s stronger consensus rating and higher possible upside, analysts clearly believe Retrophin is more favorable than its peers.
Institutional & Insider Ownership
48.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 2.9% of Retrophin shares are held by insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Retrophin and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Retrophin has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Retrophin’s peers have a beta of 6.17, meaning that their average stock price is 517% more volatile than the S&P 500.
Earnings and Valuation
This table compares Retrophin and its peers revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Retrophin||$133.59 million||-$47.90 million||-14.19|
|Retrophin Competitors||$286.20 million||$34.74 million||146.50|
Retrophin’s peers have higher revenue and earnings than Retrophin. Retrophin is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Retrophin Company Profile
Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.